The results from all of these combination therapies using anti-PD-1/PD-L1 ICBs to treat viral infection show that there is potential for this therapy, but more research needs to be conducted to determine the effectiveness and dosage levels of anti-PD-1/PD-L1 therapeutics in the context of viral infections. The gene discussed is CD274; the disease is viral infectious disease.